알테오젠, ALT-L9 바이오시밀러 식약처 품목허가 승인

The MFDS approval of Alteogen's Eylea biosimilar, ALT-L9, marks a significant step in increasing competition within the domestic ophthalmic treatment market. This move is expected to enhance patient access by lowering treatment costs and reducing the financial burden on the national health insurance system through the replacement of expensive original imports.